Confirm Your Position in the Fastest-Growing CNS Modality
With 170+ biotech and 30+ pharma actively developing CNS-targeted oligonucleotides, a collective projected market growth from $2.8 billion in 2023 to $10.6 billion by 2030, and unrelenting M&A headlines, CNS pharma and biotech are increasingly shifting their efforts towards oligonucleotide research and clinical development.
In spite of recent successes, significant challenges in translation, discovery, delivery, clinical development still persist.
This August, capitalize on the ‘oligonucleotide boom’ at the 5th Oligonucleotides for CNS Summit. Network with an exclusive group of 100+ experts and position your company as the best investment choice for drug developers seeking to gain a competitive edge.
2025 Partners:
CNS Biopharma Need Your Help With:
Why Partner?
Meet Senior Decision Makers
Network with from large pharma, who are increasing their spend in neuroscience R&D, as well as established and new biotechs, who are currently expanding their CNS pipelines.
Gain Brand Visibility
Broaden your company’s exposure at our intimate forum uniting 100+ senior biopharma leaders and build connections with the target audience you have been looking to meet.
Educate the Industry
Speak on the main agenda to leverage your expertise alongside senior KOLs to gain credibility, build trust, and distinguish your unique value proposition from your competitors
Secure New Business
With exclusive market insights curated by the Hanson Wade team, get into the crux of your customers’ pain points and differentiate your brand as the solution your customers are seeking.
Cement Your Position
Solidify your company’s role as the leading provider for your service in neurodegenerative research and development
Who Will You Meet?
